A Study of LY3971297 in Participants With Heart Failure

Exclusion Criteria

• •Have known allergies to related compounds of LY3971297 or any components of the formulation, or a history of significant atopy.
• •Had a myocardial infarction, unstable angina pectoris, coronary artery bypass graft surgery, revascularization or other major cardiovascular surgery, stroke, or transient ischemic attack in the last 90 days prior to screening.
• •Have New York Heart Association (NYHA) Class 4, acute decompensated HF (exacerbation of HF) requiring IV diuretics, IV inotropes, or IV vasodilators, within 30 days prior to screening, and/or during screening period until randomization.
• •Have SBP ≥180 mmHg at screening.
• •Have symptomatic hypotension.
• •Have resting heart rate \>90 beats per minute (bpm) at screening.
• •Have known cardiac amyloidosis, infiltrative myocardial diseases, muscular dystrophies, cardiomyopathy with reversible causes, hypertrophic cardiomyopathy, pericardial constriction, or complex congenital heart disease.
• •Have any history of moderate-to-severe stenosis of the mitral and/or aortic valve or severe mitral and/or aortic regurgitation.
• •Have any history of moderate-to-severe tricuspid or pulmonic valve stenosis or severe tricuspid or pulmonic regurgitation.
• •Have a history of syncope that, in the opinion of the investigator, may affect the participant's safety.
• •Bioprosthetic valve replacement within 12 months prior to screening or any history of mechanical valve replacement, or planned valve replacement or repair during the study period.
• •Have any history of greater than moderate pulmonary hypertension.
• •Have a pacemaker or implantable cardioverter-defibrillator placement within 90 days prior to screening.
• •Have severe chronic obstructive pulmonary disease (COPD).
• •Have clinically significant or uncontrolled cardiac arrhythmia.
• •Have a significant history of, or presence of, hepatic disease, including any abnormal liver function tests.
• •Have, within 3 years prior to screening, a history of an active or untreated malignancy or are in remission from a clinically significant malignancy (Exceptions: basal or squamous cell skin cancer).
• •For US sites: have donated blood of more than 500 mL within the previous 90 days of screening or intend to donate blood during the course of the study.
• •For Japan sites: have donated any blood within the last 4 weeks, any apheresis (blood components) within the last 2 weeks, at least 400 mL of blood within the last 16 weeks for female participants or 12 weeks for male participants, or at least 800 mL of blood for female participants or 1200 mL of blood for male participants within 12 months.
• •Other sites: Participants who have recently donated blood or blood components, or who intend to donate during the course of the study.
• •Have not been on a stable dose of medications for at least 4 weeks prior to screening, or have planned dose adjustments during the study.
• •Participants must abstain from taking new prescription or nonprescription drugs.
• •Have concurrent use or intend to use phosphodiesterase 5 inhibitor or soluble guanylyl cyclase activators.
• •Have any history of intolerance to vasodilator medications that, in the opinion of the investigator, would put them at risk of not tolerating study drug.
• •Have BP and/or pulse rate constituting a risk when taking the Investigational Medicinal Product (IMP).
• •Are diagnosed with orthostatic hypotension.
• •Show evidence of an acute infection with fever or infectious disease at screening.
• •Applicable to HFrEF participants only
• •* Have been listed for cardiac transplantation and/or anticipated or implanted ventricular assist device.
• •* Have received cardiac resynchronization therapy for less than 6 months.